Latest News

Energy Transfer could have a big year in 2026.

It's been a rough three years in the rearview mirror, but you can see 2028 through the windshield.

Target looks increasingly like a contrarian investor's dream.

It may be wise to look beyond the speculative start-ups in such a nascent quantum computing industry.

Discover why these fast-growing defense tech companies could play a major role in the future of AI and national security.

The increase should actually be bigger.

The number may not be what you expect.

Investors who don't own these seven stocks are almost certainly underperforming the broader market.

VIAVI stock passes a strict growth and momentum screen, showing a strong technical uptrend and high fundamental earnings growth.

Shares of CoreWeave have been in a tailspin over the past month, falling to levels they haven't been at since May.

Kinross Gold (KGC) shows strong technical momentum and a high-quality consolidation pattern, indicating a potential breakout. Learn the entry and exit points.

ASML assembles the most cutting-edge technology supporting the semiconductor industry.

The good news for investors is that the odds of the Federal Reserve lowering interest rates in December have increased significantly in just one week.

Economist Justin Wolfers calls Trump's tariff rollbacks a "remarkable admission" that his policies raised prices. Read the full analysis.

CADRE HOLDINGS (CDRE) aligns with the CAN SLIM method, showing strong earnings growth, high relative strength, and solid institutional support.

The teen-focused apparel brand has had a lot of publicity this year, but how has it performed over time?

JPMorgan predicts sharp decline in oil prices, with Brent crude potentially dropping to $30/barrel by 2027 due to supply outpacing demand and increased production from non-OPEC+ countries.

The UK Budget announcement will see markets weigh both fiscal and inflationary implications.

When it comes to overall utility, this $2.7 billion stablecoin really stands out.

Companies and investors see AI as a game-changing technology.

The healthcare industry is ripe for disruption.

Harmony Biosciences (HRMY) is a top GARP stock with strong growth, stellar profitability, and a surprisingly cheap valuation. A compelling growth at a reasonable price pick.

The company's headline valuation is attractive, but investors need to appreciate the longer-term picture.

Of late, this high-quality business hasn't delivered attractive returns for investors.